Can PRP Improve Symptoms of Shoulder Osteoarthritis?
Published November 16, 2026
Protocol: 7 steps in this guide
Symptoms can improve after a PRP injection, but the best direct trial reviewed here did not show that PRP works better than an alternative. In a 2022 double-blind randomized trial of 70 people with shoulder (glenohumeral) osteoarthritis, a single leukocyte-poor PRP injection and a single hyaluronic acid injection produced similar results over 12 months; both groups improved, and there was no significant difference between them. The trial had no placebo group, so it cannot show how much of the improvement either injection caused. The American Academy of Orthopaedic Surgeons’ 2020 guideline, written before that trial, did not recommend injectable biologics such as PRP for this condition.
What glenohumeral osteoarthritis is
Glenohumeral osteoarthritis is arthritis of the main ball-and-socket joint of the shoulder. The AAOS guideline on glenohumeral joint osteoarthritis, published March 23, 2020, states that it addresses osteoarthritis and is “not intended to address the management of glenohumeral joint arthritis from etiologies other than osteoarthritis,” such as rheumatoid or inflammatory arthritis.
How shoulder OA differs from frozen shoulder
Shoulder arthritis, frozen shoulder (adhesive capsulitis) and rotator cuff problems can all cause shoulder pain and stiffness, but they are different conditions with different evidence. Results from one should not be applied to another. Frozen shoulder is covered in how PRP and corticosteroid injections compare for frozen shoulder, and rotator cuff tendinopathy in what is known about PRP for rotator cuff tendinopathy. Distinguishing them is a job for a clinical examination and, where needed, imaging.
What counts as direct evidence
Direct evidence means a trial in people with diagnosed glenohumeral osteoarthritis, with PRP injected into the shoulder joint and compared with something else. The trial by Kirschner and colleagues in the Clinical Journal of Sport Medicine, Efficacy of Ultrasound-Guided Glenohumeral Joint Injections of Leukocyte-Poor Platelet-Rich Plasma Versus Hyaluronic Acid in the Treatment of Glenohumeral Osteoarthritis, meets that definition.
| Item | Detail |
|---|---|
| Design | Double-blind randomized controlled trial |
| Patients | 70 with chronic glenohumeral osteoarthritis |
| Groups | Single 6-mL injection of leukocyte-poor PRP (34) or hyaluronic acid (36) |
| Delivery | Ultrasound-guided, into the shoulder joint |
| Follow-up | 5 time points over 12 months |
| Outcomes | SPADI, ASES score, pain ratings, satisfaction, side effects |
Patient-reported pain and function outcomes
The trial found “no significant between-group differences” in SPADI, ASES and pain scores at any time point up to 12 months. Both groups improved significantly, starting at one or two months, and the improvement was seen regardless of how severe the arthritis was. Among patients given PRP, the platelet yield of the preparation had no effect on outcomes. Side effects and satisfaction were similar in the two groups.
Because both groups improved and there was no placebo group, the trial cannot separate the effect of either injection from the effect of being treated and followed. It shows that leukocyte-poor PRP was not superior to hyaluronic acid, not that either is better than no injection. Why within-group improvement is not proof of a specific effect is covered in the difference between a placebo-controlled trial and an observational study.
Why knee results cannot answer this question
Knee findings, reviewed in what the evidence says about PRP for knee osteoarthritis, do not transfer automatically to the shoulder. The joints differ, and so do the preparations and protocols studied. For the shoulder, the direct evidence reviewed here is a single trial.
Standard care and when referral is appropriate
The AAOS 2020 guideline’s statement on biologics reads: “In the absence of reliable evidence, it is the opinion of the work group that injectable biologics, such as stem cells or platelet-rich plasma, cannot be recommended in the treatment of glenohumeral osteoarthritis.” It was a consensus statement, made because reliable evidence was lacking at the time, and it predates the 2022 trial. That trial adds information but does not overturn the guideline’s caution, since it found no advantage over hyaluronic acid and had no placebo arm.
Decisions about non-surgical care, injections or referral to a shoulder specialist depend on symptoms, function and how far the arthritis has progressed, and are made with the treating clinician.
Data gaps and studies needed
The main gaps are clear from the sources:
- No placebo-controlled shoulder trial among the sources reviewed here, so the specific effect of PRP is unknown.
- A single direct trial of 70 patients, testing one preparation and a single injection.
- No evidence of structural change. The trial measured pain and function, not cartilage, and none of the sources shows that PRP regrows shoulder cartilage.
For shoulder osteoarthritis, a single injection of leukocyte-poor PRP worked no better than hyaluronic acid in the one direct trial reviewed, and the AAOS guideline does not recommend injectable biologics, so PRP remains unproven for this joint.
Cells linked to this one
This guide leads on to
- H5 PRP vs. Corticosteroid Injections for Frozen Shoulder: How Do Pain and Mobility Outcomes Compare?
- C5 What Is Known About PRP for Rotator Cuff Tendinopathy?
- I8 What Is the Difference Between a Placebo-Controlled Trial and an Observational Study?
- C1 What Does the Evidence Say About PRP for Knee Osteoarthritis?
Add a remark